glp-1 obesity drug market size 2025 The $58B Weight Loss in One Chart GLP-1 Agonists Weight Loss Drugs

Performing a preoperative assessment of RGC using point-of-care gastric ultrasound in patients continuing GLP-1RA or GIP/GLP-1RA therapy has been suggested by experts and professional societies as a risk mitigation strategy to reduce the potential for aspiration and enhance perioperative safety [17, 28, 43]

Some people stopped due to cost, while others stopped a treatment because they hit their weight loss goal or experienced side effects

Both compounds require gradual dose escalation

doi:10.1016/s0140-6736(21)01324-6 Ludvik B, Giorgino F, Jdar E, et al

Growth is supported by urbanization, public health initiatives targeting metabolic diseases, and growing demand for effective, long-term weight loss solutions in both primary and specialist care settings